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Abstract 
Background and objectives: 
The 20th century sees a revolution of translational medicine. By combining the genetics and 
bimolecular studies, many new drugs have been developed to treat infection, hypertension, 
heart failure and cancer. The use of percutaneous coronary intervention reduced the mortality 
and morbidity of acute coronary syndrome dramatically. However, there is no standard therapy 
available that can mitigate cardiac reperfusion injury, which contribute to around half of the 
infarct size. Prior studies showed that the activation of opioid receptors (OPRs), which are G 
protein-coupled receptors, induces cardioprotection both in vitro and in vivo. The exact 
mechanism of this protection is not clear yet. In addition, an FDA approved Histone 
deacetylase inhibitors (HDACi), SAHA, reduces infarct size significantly in a rabbit 
ischemia/reperfusion (I/R) injury through autophagy when it is given at the time of the 
reperfusion.  We will test whether opiate receptors protect myocardium through activating 
autophagy and whether HDAC inhibition regulates opiate receptor expressions. 
Hypothesis:  
We hypothesize that HDAC inhibition Protects Cardiomyocytes by Modulating Expression of 
Opioid Receptor and Inducing Pro-survival Autophagy by Inhibiting Class I HDACs during 
Cardiac Ischemia/Reperfusion and opiate receptors is downregulated in diabetic heart. 
Methods:  
Immortalized human ventricular myocytes (AC16) and human ES cell derived cardiomyocytes 
(hES-CMs) were treated with either DMSO or SAHA (2µM) 16 hours before subjecting to 
simulated I/R. Plate was imposed by a buffer exchange to ischemia-mimetic solution and were 
placed in a humidified gas chamber equilibrated with 95% N2, 5% CO2 to simulate ischemia. 
After 2 hour ischemia, reperfusion was initiated by buffer exchange to normoxic culture media 
with DMSO or SAHA and incubates in 95% room air, 5%CO2 for various times. The 
expression of delta or kappa opiate receptor (DOP and KOP) protein and mRNA was evaluated 
by Western Blotting and mRNA real-time quantitative PCR (qRT-PCR), respectively before 
and after I/R. In addition, nine C57BL6 wild-type mice were randomized into 3 groups: DMSO 
control, SAHA pretreatment (one day prior and at surgery), and SAHA treatment at the time 
of reperfusion only after surgery. Each surgery group was subjected to I/R surgery for 45min 
coronary ligation and 24h reperfusion. Another set of thirteen C57BL6 wild-type mice were 
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randomized into two groups, DMSO and SAHA pretreatment group without IR. To generate 
mouse type II diabetic model, we subjected mice to 50mg/Kg streptozotocin IP X 3 days then 
to high fat diet for 6 weeks. The blood glucose levels have been verified elevated compared 
with chow diet mice without STZ. Heart tissues from these mice were extracted and expression 
level of OPRs proteins and mRNA were determined by WB and qRT-PCR. 
 
Results:  
1. In AC16 cells, simulated ischemia reduces DOP and KOP expression dramatically 
around 80 %, and their levels recover almost completely in 2 hours after reperfusion (N=3, 
P≤0.005). Block of autophagy does not affect I/R regulated opiate receptor expression. 
Autophagy is downregulated after ischemia around 80% and partially recovers during 
reperfusion around 70 % ( N=3, P≤0.005). 
2. In AC16 cells, SAHA increases DOP and KOP expression around 50% and maintains 
the autophagy flux two folds during I/R by Western blots (N=3, P≤0.005). In mouse heart, 
SAHA pretreatment for 24 hours increases DOP and KOP protein around 85% and mRNA 
expression 3.5 folds by Western blots and qRT-PCR(N=3, P≤0.005). In mouse heart, SAHA 
reperfusion only treatment for 24 hours increases DOP and KOP expression around 65% by 
Western blots (N=3, P≤0.005). 
3. The expression level of DOP and KOP protein and mRNA are downregulated around 
50% in the diabetic mouse heart by Western blots and qRT-PCR (N=3, P≤0.005) respectively. 
The autophagy level is down-regulated around 63% in diabetic mouse heart (N=3, P≤0.005). 
4. In AC16 cells, Class I and II HDAC inhibitor, SAHA and Class I HDAC inhibitor, 
Apicidin induce two-folds autophagic flux (N=3, P≤0.005). While class II HDAC inhibitor, 
MC1568 does not induce autophagic flux. We observed similar results in hES-CMs.  
Conclusion:  
Delta and Kappa opiate receptors expression levels are actively regulated by ischemia 
reperfusion. HDAC inhibition increases DOP and KOP expression. In diabetic heart, DOP and 
KOP expression are reduced. Class I HDAC inhibition induces autophagic flux in 
cardiomyocytes. 
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Chapter I 
Introduction and Background 
Cardiovascular medicine grows exponentially in the 20th century, ranging from coronary 
intervention, coronary bypass surgery, heart transplantation, statin medication and effective 
heart failure medical treatment. However, despite such progress, cardiovascular disease 
continues to be the number one cause of death in the world and is estimated to be around 17 
million deaths every year. The high cost of cardiovascular disease increasingly affects state 
budgets throughout of the world.  
Today we are able to better understand the heart structure and function, their mutual 
relationship and integration with the whole organism thanks to the integration of basic research 
with clinical medicine, known as Translational Medicine. It combines the genetics and 
bimolecular cellular studies yielding potential results that can be translated into the industry 
for the development of new drugs capable of protecting the myocardium especially in the cases 
of acute ischemia. 
The heart contains highly heterogeneous and well organized cells, among them 2-3 billion heart 
muscle cells, however, they account for less than a third of the total number of cells in the heart. 
The rest are represented by a wide range of additional cells, including smooth muscles, 
endothelial cells, fibroblasts, and more recently, pluripotent cardiovascular "stem cells" which 
are all considered as permanent constituent, in contrast the impermanent cells which include 
lymphocytes and macrophages [1]. These distinct cells are not isolated from each other but 
indeed contribute to structural, electrical, biochemical, and mechanical properties of a 
functional heart and interact physically through soluble paracrine, autocrine and endocrine 
factors (Figure 1) [2]. 
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Figure 1. Schematic presentation of cardiac cell types. The adult heart consists of several cell types, 
which maintain structural, mechanical, electrical and functional integrity of the heart. A. Fibroblasts 
contribute in the formation of extracellular matrix, which provides mechanical support to the 
heart. B. Atrial cardiomyocytes contribute to contractility of atrium. C. Endothelial cells form the inner 
lining of cardiac blood vessels. D. Conduction cells generate electrical impulses for cardiac 
contractility. E. Ventricular cardiomyocytes are involved in contractility of the ventricles. F. Smooth 
muscle cells render support to the coronary arteries and vasculatures [3]. 
Ischemic Heart Disease (IHD) 
Cardiovascular disease represents the leading cause of death, morbidity and mortality and 
responsible for 17% of all health care related costs (Figure.2) [4, 5]. Ischemic heart disease 
(IHD), which comprises of primarily coronary heart disease, is the prime manifestation of 
cardiovascular diseases (CVDs) and causes 46% of mortality in men and 38% in women [6]. 
It is a leading cause of death worldwide and has become a true epidemic that respects no border 
[4]. In 2012, out of 17.5 million people died from CVDs, 7.4 million people died of IHD 
(Figure.2) [7]. Three-fourths of global deaths due to coronary heart disease occurred in the low 
and middle-income countries [8]. The burden is expected to increase more in these countries 
in 2030[7, 8]. 
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Figure 2. Ischemic heart diseases: The first cause of the death in the world [9]. 
 
Ischemia/Reperfusion Injury 
Cardiac ischemia is a condition in which heart muscle (myocardium)receive inadequate blood 
flow, so causing a shortage of oxygen and glucose needed for cellular metabolism and 
inadequate removal of metabolic wastes .It is generally caused by problems with blood vessels, 
with existing damage or dysfunction of tissue. It could be asymptomatic or may cause chest 
pain, known as pectoris. This is most frequently results from atherosclerosis, which is the long-
term accumulation of cholesterol-rich plaques in the arteries. many risk factors contribute to 
CVDs, such as smoking, aging, high cholesterol, high blood pressure, diabetes, obesity, and 
family history with CVDs [10].All of which lead to many path physiological conditions, 
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including myocardial infarction, peripheral vascular insufficiency, stroke, and shock [8]. 
Myocardial Cells response rapidly to ischemia stress, depending on the duration of ischemia, 
cell damage can be reversible or irreversible resulting in cell death. The Irreversible ones 
include mitochondrial collapses, energy depletion, large increases in intracellular calcium and 
extracellular potassium due to ion-pump deficiency, and cell swelling which all end up to a cell 
death[11]. During the ischemia phase, the myocytes undergo a number of modifications, such 
as reduction of high energy phosphates , glycogen depletion, lactate buildup, acidosis and mild 
intracellular edema (Figure 3.) [12].When re-establishing arterial flow (within 15 minutes), this 
phase of cellular suffering can be reversed by recapturing the damaged myocytes to their 
function. This reperfusion period, on the one hand, restores aerobic metabolism and promotes 
the rescue of myocyte, on the other it exacerbates (reversible) damage, developed during the 
ischemia period that can lead to new damage that causes post myocardial dysfunction [13, 14]. 
If reperfusion does not occur within the period of reversible ischemia and persists over time, 
subsequent metabolic alterations contribute to the transition from reversible damage to 
irreversible damage that manifests as necrosis and apoptosis [15]. 
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Figure 3. Ischemia/Reperfusion Phases: The myocytes undergo a number of metabolic modifications. 
mPTP, mitochondrial permeability transition pore; SR, sarcoplasmic reticulum; Cyt cytochrome c [16]. 
 
Acute Ischemia  
The complete occlusion of a coronary artery, if prolonged inevitably leads to an infraction [17]. 
At the level of local metabolism, ATP synthesis is entrusted to exogenous sources such as fatty 
acids. With the cessation of blood flow, tissue oxygen is greatly reduced and only small 
amounts of oxygen are still present in erythrocytes trapped in capillaries and bound to 
myoglobin. Oxygen release is rapidly consumed in the mitochondrial electron transport chain 
by "closing" the oxidative respiration cycle in mitochondria. It has been shown that cessation 
of mitochondrial respiration occurs already after 2 sec from the onset of global ischemia in the 
isolated rat heart [18, 19]. Ischemia induces energy metabolism to move from aerobic to 
anaerobic metabolism. Concurrently with the inhibition of mitochondrial oxidative 
metabolism, ischemia causes immediate reduction in ATP, glucose-6-phosphate, and increases 
the availability of AMP and inorganic phosphate. In turn, these metabolites and modulators 
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increase the activity of phosphorylase and phosphofructokinase causing acceleration of 
glycogenosis and anaerobic glycolysis with concomitant lactate and proton production [20]. 
An important feature of ischemia is therefore the rapid decline in ATP [21-23]. During the 
ischemia period, anaerobic glycogenosis’s becomes the first process to regenerate ATP in the 
ischemic cell. At this stage, the contractile force of the ischemic cells also decreases 
considerably when passing from aerobic to anaerobic metabolism [24-26]. 
I/R injury preconditioning 
An important observation seen in an acute myocardial ischemic model is that short periods of 
ischemia did not lead to cell death as have been seen in Acute and prolonged ischemia[27-29]. 
This phenomenon has been called ischemic preconditioning (IPC) and becomes one of the most 
effective myocardial protection strategies against episode of ischemia [30]. Today, ischemic 
preconditioning has become the paradigm of cardioprotection on which some pharmacological 
strategies are currently based. It has been suggested that ischemic insults increase calcium 
levels in the cytosol during early stages of post-ischemic and reperfusion due to sodium-
calcium pump depletion [27-30]. However, the mechanism of action of ischemic 
preconditioning remains not fully understood. 
Adenosine was the first element identified in the protective mechanism by acting both as a 
trigger and as a mediator of ischemic precondition. This effects was abolished when a non-
selective antagonist were used [28].Different types of receptors are well known to be act by 
adenosine that has a wide range of effects that make it more complex to explain the mechanism 
protection. The central role of adenosine appears to be through cellular coupling of the 
receptors for A1 and / or A3 and PKC by activating ATP-sensitive potassium channels 
(KATP).In addition to adenosine, there are other potential receptor-dependent and independent 
triggers as possible pathway signal pathways that may be responsible for induced 
cardioprotection [31]. Among this receptors are opioids, an Intracellular interaction of DOP 
and adenosine A1 receptors is indicated as an example of transactivation of GPCRs [32]. It is 
also thought that both delta and kappa OPRs which act via cellular mechanisms involving 
activation of ATP-sensitive (sarcolemma) k+ channel via G(1/o) proteins, phosphatidylinositol 
pathway via activation of kinase C, and most likely cross talk between adrenergic and OPRs in 
cardiomyocytes [31]. Nowadays, a number of studies have shown that the involvement of 
protein kinase C (PKC) in mediating anti- necrotic and anti-apoptotic actions of OPRs agonists 
[33, 34]. Studies of Maslov and colleagues have demonstrated that PI3 and Akt kinases are 
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involved in the cardioprotective effect of opioids [32, 34].Several studies have implicated 
bradykinin as a candidate trigger for preconditioning as preconditioned hearts show an increase 
of the interstitial bradykinin level associated with an increase of nitric oxide production and 
opening of KATP channels [35-37]. 
Also, it has been shown that activation of the δ-opioid receptor by opioid peptides is as a potent 
exogenous trigger of preconditioning in isolated human cardiac tissue [31] .Many reports have 
suggested that KATP channels are the downstream mechanism of cardioprotection, but the 
relative contribution of either sarcolemma or mitochondrial KATP channels to the triggering 
phase remains unclear. It has also been shown that by selectively activating the δ-opioid 
receptor with DPDPE, a selective agonist, the survival time in mice increased under hypoxic 
environments [38, 39]. Gross et al also demonstrated that ischemic PC is mediated by activation 
of the δ-opioid receptor, and by employing BNTX, a receptor antagonist, the infarct-limiting 
effect of IPC was abolished [40, 41]. 
Pharmacological conditioning   
Many drugs were tested in experimental and clinical studies as novel approaches against 
ischemia –reperfusion mainly during cardiac surgery. Desfluorane is a volatile anesthetic used 
in patients undergoing elective coronary artery that have been shown to reduce A1C myocardial 
specific enzymes and to better preserve the  postoperative contractility[42]. Also other volatile 
anesthetics such as sevofluoroin and isofluoroin have shown protective effects in animal 
experiments and reduce the level of myocardial apoptosis [43]. 
Adenosine has also been shown to have cardioprotective effects in patients undergoing 
myocardial revascularization, but the latter has not yet reached a consolidated clinical use. 
Moreover, its anti-apoptotic effect remains unclear [44].Other experimental and clinical 
evidence of cardioprotection occurred with the infusion of glucose / insulin / potassium (GIK) 
solutions in patients undergoing aortic valve replacement and myocardial revascularization. 
The GIK solution seems to prevent apoptosis at least in an experiment that induced an ischemia 
/ reperfusion in an animal model[45].Interesting is the use in a cardiac surgery of a well-known 
drug as the main immunosuppressant in organ transplants such as cyclosporine A[46].This drug 
acts as a specific inhibitor of mitochondrial pores (MPP) and therefore acts as an anti-apoptotic 
drug through the action of bradykinin. Antioxidants and calcium antagonists and anti-
inflammatory drugs such as corticosteroids have all shown protective effects in clinical trials 
[47].In experimental models, intracoronary infusion of insulin-like growth factor (IGF II) 
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appears to prevent apoptosis and the release of myocardial specific enzymes such as troponin 
I. Minocycline, a tetracycline family antibiotic, and some peptides have been shown to have 
anti-apoptotic effects in experimental models [48, 49]. 
Opiate receptor in I/R injury preconditioning 
Manglik and colleagues have described opiates as most efficient analgesic drugs for long 
decade. In order to be activated, They bind to opioid receptor (OPRs) [50].Opioid receptors are 
G-protein coupled receptors(GPCRs),that regulate neurotransmission and can activated by both 
endogenously produced opioid peptides or exogenously administered opiate compounds [51]. 
This receptors include four major subtypes,i.e.mu(MOP),delta(DOP),kappa(KOP),and 
nociceptin receptor(NOP)identified by molecular cloning. Their proposed names based on the 
first ligand that was found to bind to the receptors [52].Each of the cloned OPRs is derived 
from a single gene; however, alternative spliced variants from their own genes have been 
isolated [53]. The three classic closely related subtypes, mu, delta and kappa, share similar 
sequence identity in their helices structures [54, 55] (Figure.4, Table. 1), with more variations 
in extracellular loops and very little similarity in their amino and carboxyl terminal[51, 
56].Anatomical and molecular studies indicate their presence in many peripheral tissues such 
as, heart[57, 58],intestines, adrenal medulla, kidney, lung, spleen, testis, ovary and uterus [59], 
skin[60] . 
Major families of the opioid system are derivatives of the endogenous peptides pre-
proopiomelanocortin, pre-proenkephalin A and pre-proenkephalin B [61]. Furthermore, 
opioids, sometimes considered as neurotransmitters, and possess autocrine, paracrine, or 
endocrine functions in the peripheral tissues [33, 62, 63]. 
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Figure 4. Opioid receptors helices structure. Seven transmembrane domains, the extracellular and 
intracellular loops that is important for receptor activity and protein-protein interactions[64]. 
 
 
Table 1. Opioid receptor types and classification [65]. 
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Myocardial opioid expression 
As a high level of endogenous opioids is expressed in the heart [66, 67], many researchers were 
aimed to better understand their link with cardiovascular disease conditions such as myocardial 
infarction, stunning, and arrhythmia. They have been shown to regulate cardiovascular function 
in the healthy and diseased heart [68]. Clinically opioid  are given to patients with advanced 
heart failure [69] as painkiller  and their effects on cardiovascular function are most known to 
reduce arterial hypotension and bradycardia[70]. The term ischemic preconditioning and 
cardioprotective effects by OPRs was mentioned in many publications in different animal 
models [31, 71]. 
Opioid peptides synthesis and releases by myocardial were variable in different cell condition, 
influenced by aging and disease state[72] preserved and activated by I/R [73], and many are 
related to a greater generation of endogenous DOP selective ligands [66, 67] have shown that 
ventricular myocardium contain highest levels of pre-proenkephalin and that may explained 
the heart as an important neuroendocrine organ. The term ischemic preconditioning and 
cardioprotective effects by OPRs were mentioned in many publications in different animal 
models [71]. 
On a cell surface a series of chemical and physical events reactions produce biological 
responses once an opioid binds to their receptors, including proliferation, cell differentiation, 
metabolism alteration, cell growth, division, survival, and apoptosis [74]. Intracellular 
signaling molecules diffuse to their spatial target molecules in the cytosol and/or nucleus 
resulting in programmed changes in gene expression [75]. They have three major classes such 
as cyclic nucleotides (e.g. cAMP&cDMP), Inositol triphosphate (IP3), Diacylglycerol (DAG), 
and calcium ions (Figure 5). 
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Figure 5. Binding of opioid and activation of G-proteins. Opioid receptor triggers 
activation of G-protein, which then activates a specific second messenger [76]. 
 
 
Functions of Opioid Receptors 
Opioids are well known in pain modulation and widely associated with analgesia for 
postoperative pain therapy [77].In the heart, it has been shown an elevation of β-endorphin 
following muscle injury and hemorrhagic shock in naïve rats models [78]. 
The delta and kappa opioid receptors have been shown to mediate cardioprotection by 
preconditioning with myocardial ischemia and metabolic inhibition [54, 71].Evidence 
regarding the role of local opioids and opioid receptors in regulation of cardiovascular 
physiology and I/R has shown that activation of opioid receptors in the reduction of myocardial 
I/R by selective δ-opioid agonists when given acutely before ischemia and reperfusion [79].In 
a study, using administration of a potential and selective kappa opioid agonist, it has also shown 
antiarrhythmic effects depending on the activation of the-opioid receptor [80]. 
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Opioid receptors, especially, DOP, mediate neuroprotection against ischemic injury. Even 
though there have been major controversies in the past decade on the role of opioids in the 
neuronal responses to ischemic insults by activation and inhibition of opioid receptors, recent 
data have clarified their neuroprotective effects against ischemic neuronal injury [81, 82]. The 
up-regulation of DOP expression and activation increase the neuronal tolerance to ischemic 
stress through triggering different mechanisms (PKC-ERK-Bcl2), and stabilization of ionic 
homeostasis [81] that reduce oxidative [83] and glutamate-induced [84] injury to reserve 
neuronal survival [83]. DOP also play a crucial role in neurogenesis. It is indicated that DOP 
agonist (SNC80) promotes neural differentiation from multipotent neural stem cells [85]. 
Opioids sometimes, act like cytokines to modulate the immune response in central and 
peripheral neurohumoral systems [86]. OPRs stimulation exerts suppression in numerous parts 
of the immune defense responses[87]. Opioid modulation of the immune response is mediated 
via the direct interaction with OPRs expressed by immune cells [88].They are also involved in 
regulation of ionic homeostasis under normoxic and ischemic conditions by intracellular 
elevation of Ca2+ or inhibition of their entry. 
Opioid receptors are also involved in regulation of feeding in animal. Stimulation of OPRs 
increases feeding, while inhibition of OPRs reduces food intake in rodent models of obesity 
[89]. 
It has been well established that opioids trigger respiratory depression in humans and animals 
by a direct action on respiratory generating and high densities of OPRs brain areas [90, 91]. 
The use of opioid drugs for pain relief results in a respiratory depression that creates a 
significant clinical problem for patients treated with the drugs in the postoperative period 
[90].The massive release of endogenous opioids or overdose of opioid drugs can cause a severe 
respiratory depression and may be lethal. On the other hand, excessive use and abuse of opioid 
compounds lead to opioid tolerance/addiction in the nervous system via desensitization and 
internalization which greatly affects body homeostasis and brain physiology[92]. 
 
  
24 
 
Opioid receptors cardioprotective action signal mechanism 
Mechanisms of OPRs which are involved in cardioprotection are not clearly understood. It was 
supported that the occurrence of convergent pathways in which multiple GPCRs interact 
independently and transactivate epidermal growth factor (EGF) receptor-dependent kinase 
signaling to provide cytoprotection [34]. Intracellular interaction of DOP and adenosine A1 
receptors is indicated as an example of transactivation of GPCRs [32].It is also thought that 
both delta and kappa OPRs which act via cellular mechanisms involving activation of ATP-
sensitive (sarcolemma) k+ channel via G(1/o) proteins, phosphatidylinositol pathway via 
activation of kinase C, and most likely cross talk between adrenergic and OPRs in 
cardiomyocytes [33]. It is known that Gi/o proteins are intermediary linkages that provide 
cellular signaling between OPRs and protein kinase C (PKC).  
Nowadays, a number of studies have shown that the involvement of protein kinase C (PKC) in 
mediating anti- necrotic and anti-apoptotic actions of OPRs agonists that involve PI3 and Akt 
kinases are mediating the cardioprotective effect of opioids [32, 34]. Besides, important roles 
of MEK1/2, ERK1/2, Src and JAK2 kinases and transactivation of OPRs in the cardioprotective 
effect of opioids in the development tolerance of the heart to ischemia and reperfusion are 
indicated and opioid transactivation of epidermal growth factor receptor (EGFR) is a 
connecting link between OPRs and ERK1/2 and PI3 kinase cascades [34].The activation of the 
EGFR increases the Akt (protein kinase B) and Pl3 (phosphatidylinositol-3-kinase) in their 
activities [93](Table 2). 
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Table 2. Summary of opioid receptor-dependent signaling [76]. 
 
In the past decades, various investigators have shown their efforts to find out possible 
mediating effects of OPRs against IR injury using different: pharmacological, ischemic and 
exercise preconditioning. DOP and KOP are strongly implicated in cardioprotection including 
anti-infarct and anti-arrhythmic actions across models and species (Table 3). 
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         Table 3. Opioid Receptors Sub-Types and Function [94]. 
 
 
 
Opiate Receptor in Diabetes Mellitus 
Type 2 diabetes is a common heterogeneous metabolic disorder which is influenced by genetic 
and several non-genetic factors including excess caloric intake and physical inactivity 
[95].According to the World Health Organization’s estimation, more than 180 million people 
worldwide have diabetes mellitus (DM) [6]. This number is expected to increase more than 
double by 2030. Approximately 1.1 million people died from diabetes in 2005. Roughly half 
of diabetes deaths occur in people aged below 70 years and 55% of diabetes deaths are in 
women [6, 9]. There is a considerable increase in the incidence of this disease and it is widely 
recognized as a strong independent risk factor for coronary heart disease (CHD) especially 
among women [96]. Thirty percent of all patients undergoing aortic coronary artery bypass 
(CABG) are diabetic, these patients have post-operative mortality and mortality rates higher 
than the non-diabetic population with mortality rates of up to 50% to 90%. Myocardial 
infarction and Cardiac morbidity followed by stroke are among the common causes of late 
mortality after CABG in DM patients [97]. Compared to non-DM, these patients exhibit higher 
postoperative morbidity with higher percentages of higher re-interventions, decking, infections 
,higher incidence of postoperative neurological complications and longer hospitalization 
periods [98, 99].It although reported that greater oxidative stress induced by cardiopulmonary 
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bypass (CPB) in DM patients than those without DM .In addition, both early and late mortality 
is certainly higher in DM patients[100]. Differences in the gene expression profiles of cardiac 
myocytes in DMP patients compared to non-diabetic NDMPs, particularly those related to 
inflammatory response and oxidative stress has been addressed as well as cardioprotective 
effects by opioid receptors [101].Hyperglycemia before and after cardiac surgery, in addition 
to inducing oxidative stress in the heart , contribution of coronary endothelial cells to cardiac 
adenosine production; It has been shown to cause mitochondrial dysfunction, cytochrome c 
release, and apoptosis . 
Although, It has been reported that PKC, PI3 kinase/Akt, ERK1/2, STAT3, and GSK-3β 
phosphorylation impairment in diabetic hearts are the possible potential mechanisms that make 
the diabetic hearts more susceptible to IR and less sensitive to opioid conditioning [102]. 
However ,Mechanisms through which DM increases morbidity and mortality in myocardial 
revascularization and the role of opioid receptors on cardioprotection beside the multi functions 
of OPRs in cardiovascular physiology and neurotransmission, their expression in diabetic 
hearts, their cardioprotective roles in diabetes models of mice heart through Hdac inhibitor 
have not been evaluated yet. Thus, our study may contribute to better understand the important 
cardioprotective role of opioid receptors (particularly DOP, and KOP ) in the STZ-induced 
diabetic mice model treated with HDAC inhibitor. 
Histone Deacetylase Inhibition in I/R Injury 
Histone deacetylases (HDAC) are a class of enzymes that remove acetyl groups (O=C-CH3) 
from a ε-N-acetyl lysine amino acid on a histone (or proteins) by the histone acetyltransferases 
(HATs) to allow the histones to wrap the DNA more tightly[103](Figure 6).This process is a 
vital aspect of epigenetic regulation of gene expression and more generally for the control of 
cellular stability that is regulated by acetylation and de-acetylation. In 1996 Taunton open the 
window to characterize the biochemical feature of the histone deacetylase after he succeed to 
clone and isolated HDAC1 for the first time[104].Indeed many article were published notably 
after this success. Today it is well known that HDACs play crucial roles in gene transcription 
and most likely in all eukaryotic biological processes that involve chromatin (Figure 7). 
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  Figure 6 .Acetylation and Deacetylation. Key role for genes regulation [105]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Multiple HDACi Pathways[106]. 
 
In mammalian cells, 18 HDACs have been described, grouped into 4 classes based on sequence 
homology and phylogenetic relationship [107]. Class I comprises HDACs 1, 2, 3, and 8, which 
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are located within the nucleus; class II comprises HDACs 4, 5, 6, 7, 9, and 10, which are located 
in both the nucleus and the cytoplasm; and class IV comprises HDAC 11 (Table 
4)[108].HDACs also regulate the post-translational modification such as acetylating status of 
many non-histone proteins, including transcription factors, chaperones, and signaling 
molecules, resulting in changes in protein stability, protein-protein interactions, and protein-
DNA interactions that regulate cell proliferation and cell death (Table 5) [109]. 
 
Table 4 .HDAC Classifications [110]. 
 
 
 
 
 
 
 
 
Table 5 .Non-Histone protein substrates of HDACs[106]. 
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So, it is not surprising that Epigenetic changes caused by imbalances between HATs and 
HDACs can affect global transcriptional profiles. In facts, HDAC knockout mice and gene 
deletion and/or overexpression studies have revealed important functions of several of these 
enzymes that are linked strongly with cardiovascular diseases, including coronary heart 
diseases [111], diabetic cardiomyopathy [112], hypertension [113, 114], ventricular 
remodeling [115, 116], and arrhythmia [117]. In addition, HDAC1 knockout mice have shown 
an embryonic lethal phase HDAC2 knockout mice are born alive but have severe cardiac 
defects and die within 24 hours [116].Conditional knockout of HDAC3 in cardiomyocytes 
leads to a dramatic upregulation of ligand-induced lipid storage within the heart. The mice 
survive for 3–4 months, at which point they show massive cardiac hypertrophy and depression 
of the genes that control fatty-acid uptake and metabolism [11]. HDAC5 and HDAC9 
knockouts also have severe cardiac effects, including hypertrophy and fibrosis and were lethal 
with ventricular septal defects and a thin-walled myocardium (Table 6) [117]. 
They are extremely important in disease and now days are the target of many drugs.  HDAC 
inhibitors (HDACi’s) are common drugs for treating cancers, neurodegenerative diseases, and 
metabolic disorders to name a few [118]. HDACs inhibition results downstream changes in 
gene-expression promoting their therapeutic properties[119]. HDACi’s have long been used in 
cancer treatments as well as in treating neurological condition. It has been reported   that 
increased histone acetylation in the brain is associated with memory formation, while decreased 
acetylation reverse this effect [120, 121].  
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    Table 6. Summaries of the various HDAC knockout phenotypes [122]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
They have demonstrated potent cardioprotective effect of a selective inhibition of classes I and 
II HDACs, trichostatin A (TSA) in murine models of myocardial ischemia/reperfusion (I/R),by 
reducing infarct size and preserved systolic function[123, 124] . This is in line with the 
observations that inhibition of HDACs in cardiac myocytes silences fetal gene activation, 
attenuates cardiac hypertrophy, and prevents cardiac remodeling [115, 125]. Also, TSA was 
recently reported to improve myocardial function and prevent cardiac remodeling in diabetic 
mice [126]. 
More interestingly, TSA giving at reperfusion only and after the ischemic insult still reduced 
infarct size to an extent similar to pretreatment [124, 125].These exciting results suggest that 
HDAC inhibition would be a novel drug strategies to patients presenting with myocardial 
infarction at the time of percutaneous coronary intervention in the cardiac catheterization 
laboratory. This idea has its own limitation because of large differences in the disease 
mechanisms in murine models and human case as previously reported. Based on this facts 
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,another HDAC inhibitor that is structurally similar to TSA, suberoylanilide hydroxamic acid 
(SAHA; vorinostat) (Figure 8),which is approved by the US Food and Drug Administration 
(FDA)for the treatment of cutaneous T-cell lymphoma, has been tested in a large-animal model 
of I/R by Min Xie (et colleagues 2014)  and they have demonstrated a cardioprotective effect 
of SAHA ,by inducing prosurvival autophagy[127]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure 8. Chemical structure of SAHA and TSA[128]. 
Autophagy and Molecular Mechanism  
Autophagy (self-eating) a well conserved dynamic process which is present in all cells. It 
results in the degradation of cytosolic components inside lysosomes in preparation for the 
turnover and recycling of cytoplasmic contents (e.g. proteins into amino acids or nucleic acids 
into nucleotides) [129]. Glick and colleagues have described three types of autophagy in 
mammalian cells, macroautophagy, microautophagy and chaperone-mediated autophagy 
(CMA) respectively (Figure 9.) [130]. 
Macroautophagy is characterized by the delivery of cytoplasmic cargo to the lysosome through 
an intermediary double membrane-bound vesicle, known as an autophagosome, which fuses 
with the lysosome to form an autolysosome. Whereas, in microautophagy a direct engulfment 
of degraded contents through invagination of the lysosomal membrane [129, 130]. CMA 
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involves the direct translocation of cytoplasmic proteins across the lysosomal membrane in a 
complex with chaperone proteins receptor LAMP-2A (lysosomal-associated membrane protein 
2A), resulting in their unfolding and degradation[131]. 
The processes of autophagy consist of three stages: Induction, autophagosome formation and 
fusion for degradation and recycling (Figure10).Briefly, in response to various 
stimuli, autophagy is induced by formation of a unique flat membrane (phagophore). The 
initiation requires two protein complexes involved in the regulation of autophagosome 
formation.The elongation of the phagophore results in the formation of an autophagosome, a 
double-membrane organelle. This step is a simple sequestration, and no degradation 
occurs.LC3B-II is found on both the inner and the outer surfaces of the autophagosome. During 
autophagy, the synthesis and processing of LC3 is increased and it is used as markers to monitor 
levels of autophagy in cells. Completely formed autophagosome are fused with the lysosomes 
in the cell. Autophagosome-lysosome fusion is mediated by the same machinery that is 
involved in homotypic vacuole membrane fusion [131-133]. 
The degradation of the vesicular cargo is dependent on a series of lysosomal/vacuolar acid 
hydrolysis. The resulting small molecules from the degradation, particularly amino acids, are 
transported back to the cytosol for protein synthesis and maintenance of cellular functions 
[134]. 
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Figure 9. Types of autophagy in mammalian cells. Three main forms of autophagy exist: 
macroautophagy, microautophagy and chaperone-mediated autophagy. Internalized substrates could be 
different cytosolic organelles (circles) and/or single proteins [133]. 
 
Figure 10.Steps of autophagy. Autophagy begins with the formation of the phagophore (vesicle 
nucleation step). Then, expansion of the phagophore into an autophagosome (vesicle elongation) taken 
place. Finally, the outer membrane of the autophagosome fuses with an endosome to form an 
autophagolysosome where, the sequestered material is degraded inside and recycled [135]. 
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The Important Role of Autophagy 
Many Genetic studies have emphasized the importance of autophagy in physiological and 
pathological events such as cancer, metabolic and neurodegenerative disorders as well as 
cardiovascular and pulmonary diseases. It also has been associated in aging and exercise in 
various organisms’ models [136]. 
Autophagy at basal level has an important housekeeping role allowing cells to survive by 
supplying nutrient as shown in yeast and neonatal mice [137]. Also it has a role in cellular 
remodeling during differentiation and the development of multicellular organisms [138-
141].Moreover, constitutive autophagy, which occurs independently of nutrient stress plays a 
key role in immune defense against invading bacteria and pathogens, and regulates 
inflammation, antigen presentation and micro-organism capture and degradation also, it 
contributes to liver homeostasis in animal model [141] (Table7). 
It has been reported the protective role of autophagy in neurodegenerative diseases by 
removing unwanted cellular organelle and protein aggregates and in contrast, deletion of 
specific autophagy genes reverse this effect [142-147]. Although autophagy was linked to 
cancer, in a way to overcome nutrient-limiting conditions and facilitate tumor growth by 
promoting angiogenesis, supplying nutrients, and by modulating inflammatory response [148].  
 
     Table 7. Possible Autophagy outcomes in different pathologies [133]. 
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Autophagy and Cardioprotection 
The exponential growing of research has led to better understand the physiological functions 
attributed by autophagy and its role in many diseases. Besides that , when analyzing this role 
independent of the specific details of each disorder, a challenge is to determine whether 
autophagy protects or contributes to cell damage. In fact, depending on the intensity and 
duration of the insult autophagy could be a protective process or a cell death precursor therefore 
Autophagy termed as a double sward edges [149-151]. Perhaps, this is the reason for cardiology 
literature to pay a little attention to autophagy as a cellular protective mechanism. Here, we 
mainly focus on their protective effect in the heart. Recently ongoing research using 
experimental model and novel therapeutic drugs induce cardioprotective autophagy. It has been 
reported that autophagy occur during short periods of ischemia, however its contribution, for 
example, to preconditioning has not been studied yet. Classic autophagocytic vesicles and 
autophagy have been observed in the rabbit hearts made of hypoxia for 20-40 minutes and then 
reperfused and this is was associated with the functional recovery of myocytes [152, 153]. 
Min Xie and colleagues demonstrate that an FDA-approved HDAC inhibitor, SAHA, reduces 
myocardial infarct size in a rabbit-animal model by activation of cardiomyocyte autophagy, 
however the molecular mechanisms underlying this promising cardioprotective effects remain 
unknown. Thus our study may contribute to better understand the cardioprotective effect of 
autophagy in the heart. 
Major Deficiencies in Our Present Knowledge and Hypotheses 
Based on our introduction, the important role of opioid receptors to protect myocardium is an 
attractive field. Although a lot of studies have been done, still the role of opioid receptors is 
not well understood especially in the heart. With the knowledge that an FDA approved drug, 
SAHA, protects the heart during I/R in a rabbit large animal model by inducing pro-survival 
autophagy. It is not known whether Delta and Kappa opiate receptors expression levels are 
regulated by ischemia reperfusion and HDAC. Furthermore, it not known whether opiate 
receptor expression levels are changed in diabetic heart. Although we know Class I and II 
HDAC inhibitor, SAHA induces autophagy in the heart, it is not known which class of HDAC 
inhibitor is responsible for inducing autophagic flux in cardiomyocytes. 
We hypothesize that HDAC inhibition Protects Cardiomyocytes by Modulating Expression of 
Opioid Receptor and Inducing Pro-survival Autophagy by Inhibiting Class I HDACs during 
Cardiac Ischemia/Reperfusion and opiate receptors is downregulated in diabetic heart. 
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This study was designed to evaluate by quantitate and qualitative approach the expression of 
opioid receptors and their mRNA levels, in vitro and in vivo wild type mice  and STZ-induced 
diabetic  mice (Figure 11) . Our study will lead to better understand the role of OPRs 
specifically with the treatment of an approved HDACi drug such as SAHA.  
Figure.11 Flow chart of hypothesis. 
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Chapter II 
Experimental procedures 
Human immortalized ventricular myocytes Cell culture (AC16) 
The AC16 cells were cultured in plate coated with 0.1% gelatin and incubated in high-glucose 
Dulbecco's Modified Eagle Medium (DMEM, Hyclone, USA) with 10% fetal bovine serum 
(FBS) ,1.3% Hepes and 1% penicillin/streptomycin at 5% CO2 and 37 °C up to80% confluence 
.Than AC16 cells were differentiated in HS 2% for 48 hours before starting their proper 
treatment. 
Primary culture of Neonatal rat Ventricular myocytes (NRVM) 
In brief, LVs from 1- to 2-day-old Sprague-Dawley rats were collectedand digested with 
collagenases. The resulting cell suspension was pre-plated to clear fibroblasts. Then the cells 
plated at a density of 1250 cells per 1 mm2 in medium containing 10% fetal bovine serum with 
100 μmol/L bromodeoxyuridine. Typical cultures were notable for >95% cardiomyocytes. 
After overnight culture, medium with 10% horse serum was added for 24h, and then cultured 
in serum-free medium for 24 to 48 hours until further treatment. 
Simulated I/R in Cultured Cells  
For simulated ischemia/reperfusion (I/R) AC 16 or NRVM cell, ischemia was imposed by a 
buffer exchange to ischemia-mimetic solution (in mmol/L: 20 deoxyglucose, 125 NaCl, 8 KCl, 
1.2 KH2PO4, 1.25 MgSO4, 1.2 CaCl2, 6.25 NaHCO3, 5 sodium lactate, 20 HEPES, pH 6.6) 
and placing the culture plates within a humidified gas chamber equilibrated with 95% N2, 5% 
CO2. After 2 hours of simulated ischemia, reperfusion was initiated by buffer exchange to 
normoxic AC16 culture medium or NRVM With HS2% OR 10% fetal bovine serum 
respectively, and incubation in 95% room air, 5% CO2. Controls incubated in normoxic culture 
medium for each kind of cells that were prepared in parallel for each condition. 
siRNA knockdown in tissue culture 
NRVMs were isolated and seeded at a density of 1.2 million/well in a 6-well dish. The purity 
of the cardiomyocytes is at least >85%. 24 hours after plating, cardiomyocytes were incubated 
with siRNA negative control (Neg, SIC001), siRNAs targeting DOP (SASI_Rn02_00259814), 
and siRNAs targeting KOP (SASI_Rn02_00261483), both from Sigma and used according to 
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the manufacturer’s recommended protocols. Briefly, siRNAs were reconstituted into a 40 mM 
stock solution. 8μL of the siRNA stock and 8μL of RNAiMax transfectant were mixed together 
in 1 mL Optima medium. Cardiomyocytes were incubated with the RNAiMax for 6 hours, 
followed by addition of 1 mL of culture medium containing 20% serum. 24 hours after the 
siRNA incubation, the cardiomyocytes were treated with SAHA at 2μM (overnight). Then, the 
cells were subjected to ischemia (2 hours) and reperfusion (2 hours) for either immunoblotting 
or cells death assay. 
Western blot analysis 
Total proteins were extracted from myocardial tissues and Ac16 cells.  Cells were lysed in 20 
mM HEPES, pH 7.4, 2 mM EGTA, 50 mM glycerophosphate,1% Triton X-100, 10% glycerol, 
1 mM dithiothreitol (DTT), 2 µg/ml leupeptin, 5 µg/ml aprotinin, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM Na3VO4. Protein concentration was measured using BCA assay .Forty 
µg were loaded on 12.5% SDS polyacrylamide gels and then transferred in wet transfer 
containing 25 mM Tris-base, 0.2 M Glycine, 20% Methanol, pH 8.5 for 2 hours in 450 mA 
into polyvinylidene difluoride (PVDF) membranes . The PVDF membranes were blocked 
with5% non-fat milk in TBS-T (0.1% Tween-20, AppliChem, Germany for 1 h. The primary 
antibodies such as Oprd1 (DOP), Oprk1 (KOP) (Santa Cruz biotechnology sc-9111, sc-7494) 
respectively, LC3I-II (Apg8b, Abgent San Diego, California, Us), P-62 (5114-Cell Signaling 
Technology, Danvers, US), and GAPDH (10R-2932-Fitzgerald, US) were incubated with 
agitation overnight at 4 °c. GAPDH was used as internal control. The secondary antibodies 
anti-goat (sc202-sigma), anti-mouse (Na931v,Ge Healthcare Bio-Sciences,Pittsburgh,US) 
secondary anti-rabbit (Na934v, Ge Healthcare Bio-Sciences,Pittsburgh,US) were incubated for 
another 1∼2 hours at RT after have been washed three times in TBS-T . Amersham imaging 
system (Ge Health Care, Marlborough, US) and ImageJ software was used to acquire and 
analyze the intensity of band respectively. 
RNA isolation 
Samples from myocardial tissues (~50mg) were homogenized with 1ml Trizol reagent 
(Invitrogen, Carlsbad, USA). Chloroform (200µl) was added to each Eppendorf tube and 
shacked vigorously by hands and then pre-incubated for 5 min at room temperature (RT) before 
centrifuged at 12, 000rpm for 15min at 4 oC. The upper supernatant was transferred to new 
Eppendorf tube .Isopropanol (500ul) was added to each tube and incubated at RT for 10min. 
Following 10min centrifugation at 12,000rpm, the supernatant was discarded and the pellet 
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was washed 2 times with 1 ml of 70% of ice cold ethanol. The ethanol was discarded and 
removed carefully by pipetting. After 10min air dry 20-50µl RNase-free water was added to 
suspend the RNA-pellet and incubated at 60oC for 10min in a water bath. Finally, RNA 
concentration was measured by Nanodrop and stored at -80oC until required. 
Synthesis of cDNA 
Complementary DNA (cDNA) were synthesized by using high-capacity cDNA reverse 
transcription kits (Applied Biosystems, Carlsbad, USA) according to the manufacturer's 
instructions. The following reagents were added to aPCR micro centrifuge tube on ice in the 
first mix: Total per reaction 10µL:10X RT Buffer 2µL , 25X dNTP Mix (100 mM) 0.8 µL, 
10X RT Random Primers 2µL, MultiScribe™ Reverse Transcriptase 1µL, and Nuclease-free 
H2O 4.2 µL. The mixes were centrifuged gently and briefly .Then 10μL of RNA (250ng) 
sample were added, mixes well up and down. The contents were spinet down to eliminate any 
air bubbles before placing it in the thermal cycler at 25°C for 10minutes, 37°C for 120 minutes, 
85°C for 5 minutes, and 4°C time to collect and were stored at -80°C until usage.  
Quantitative Real-Time PCR 
Real-time PCR (qPCR) was performed with the 7500 Fast Real-Time PCR System (Applied 
Biosystems) using the SYBR Green PCR Master Mix Kit (Applied Biosystems, Carlsbad, 
USA) that contains all components except primers and cDNA template. Following primer mix 
for Oprd1 (DOP), Oprk1 (KOP) (SIGMA-Aldrich), relative expression levels of was 
determined. As an internal control GAPDH (Invitrogen, 059901, M5583 (A02, A01) was used. 
the data calculated by the delta-delta method as indicated previously [154].  
   Table4: Primer sequence used for real-time PCR (qPCR-RT). 
Animals and experimental design 
All animals were handled in this study in accordance with the standards established in the 
Guide for the Care and Use of Laboratory Animals published by the Institute of Laboratory 
Animal Resources of the National Research Council (United States) and approved by the 
Gene Forward mouse (5`-3`) Reverse mouse (5`-3`) 
OPRD1 CGGTACACCAAATTGAAGAC GTTGTAGTAGTCAATGGAGAG 
OPRK1 AAAGTTGTGCCTCTATTGTG TTGAAAACTGTCATGGTCTG 
GAPDH ATCAGCAATGCCTCCTGCAC TGGTCATGAGTCCTTCCACG 
 
  
41 
 
Animal Care Committee of the University of Alabama at Birmingham. Wild-type male 
C57BL/6 mice used in this study were housed under identical conditions in a pathogen-free 
environment with a 12:12h light/dark cycle and free access to laboratory chow and water. 
Mouse model of I/R 
For I/R surgeries, 8 to 12-week-old C57BL/6 wild-type mice were utilized. C57BL/6 wild-type 
mice were anesthetized with 2-4% isoflurane and placed in a supine position on a heating pad 
(37°C). Animals were intubated with a 19G stump needle and ventilated with room air using a 
MiniVent mouse ventilator (Hugo Sachs Elektronik; stroke volume 250 µL, respiratory rate 
210 breaths per minute). Following left thoracotomy between the second and third ribs, the 
LAD (Left Anterior Descending coronary artery) was visualized under a microscope and 
legated using a 6–0 prolene suture. Regional ischemia was confirmed by visual inspection 
under a dissecting microscope (Leica) of discoloration of the occluded distal myocardium. For 
I/R, the ligation was released after 45 minutes of ischemia and the tissue allowed to re-perfuse 
as confirmed by visual inspection.24 hours of reperfusion was performed after 45 minutes 
ischemia. Then the mice were sacrificed, the heart was extracted and tissue was used for 
subsequent Western blot, RNA isolation for further analyses. 
 
 
 
 
 
 
 
 
 
                    Figure 12. Simulated I/R Injury and mouse I/R Models. 
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Drugs preparation 
SAHA and bafilomycin were purchased from LC Laboratory, were dissolved with DMSO to a 
final concentration of 2mM and 1mM respectively and aliquots in small tubes at -20c until 
further usages for cell treatment. SAHA injected to mice was freshly prepared [127]. Naloxone 
(E5008, D8147and product number from sigma were dissolved in sterile water 
(10mM).Streptozotocin (STZ) mixed anomers (STZ, product ref. S0130-500MG, Lot. No. 
WXBC2044V, SIGMA-Aldrich Chemie GmbH Kappelweg Schnelldorf, Germany) was dilute 
in 1ml of citrate buffer (10mM, pH 4.5) freshly prepared. 
Diabetic mouse model 
In STZ-induced model of diabetic mice prepared as previously described [155] .briefly,  8-12-
week-old C57BL/6 wild-type mice were received IP injection of STZ dissolved in 10mM 
citrate buffer (45.5ml 0.1M citrate acid and 55.5ml 0.1M Na2HPO4, pH 4.5)  at 40mg/kg  after 
4h fasting for 3 consecutive days. Mice were placed on high fat diet until the end of 
experiments. The survival rate was 100%. 
Body weight and fasting blood glucose level measurement 
Body weights of all groups of the rat were taken before STZ injection and after three and sixth 
weeks of IP injection.  The blood collection site of the tail was wiped with 70% ethanol prior 
to place droplet of blood on a glucometer test strip. A blood sample obtained by pricking the 
lateral tail vein using a sterile needle and then the blood was gently milked from lateral tail 
vein and placed droplet of blood on a glucometer test strip and read using STATSTRIPXpress-i 
glucometer mg/dl (SN 138038215324, Nova Biomedical UK) and STAS-STRIP GLU 
SENSOR (Lot: 0315123309). Fasting blood glucose levels was measured after three and six 
weeks of STZ-induction. The mice in all groups were sacrificed after six weeks. 
 
                     Figure.13 Type II diabetic mouse model. 
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Statistical analysis 
Statistical analysis of the differences among groups was evaluated with a one way ANOVA 
followed by Duncan’s multiple-comparison test using SPSS software (version 19.0, SPSS Inc., 
Chicago, IL, USA). Significant differences were established at the level of p < 0.05. Data are 
expressed as means ±SEM. 
Chapter III 
 
RESULTS 
PART-I Regulation of Opioid Receptors by I/R and SAHA. 
OPRs are highly regulated receptors and has high expression level in in the heart [66, 67]. 
We are set to study the expression of OPRs in the setting of ischemia/reperfusion. 
Furthermore, we will look the effect of HDAC inhibition. 
Opiate receptor expression is regulated by I/R.  
In a vitro system of simulated I/R, we have evaluated the expression of OPRs in a time course 
manner (reperfusion for 30 min, 60 and 120min respectively) after 2h of ischemia. Simulated 
ischemia reduces DOP and KOP expression dramatically around 80 %, and their levels recover 
almost completely in 2 hours after reperfusion (N=3, P≤0.005) (Figure 14). Furthermore we 
have test whether autophagy is affected by I/R in Ac16 cell, by using baflomcycin (BFA), an 
autophagy inhibitor, and treatment for 2 hours. This blockage does not affect I/R regulated 
opiate receptor expression. However the trend of LC3II levels is similar to that of OPRs. During 
ischemia, autophagy measured by LC3II level is downregulated after ischemia ~ 80% and 
partially recovers during reperfusion for around 70 % (N=3, P≤0.005) (Figure 14). These 
indicate that autophagy and OPRs correlate to each other during cellular response to I/R injury.   
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 Figure 14. Opiate receptor expression is regulated by I/R. A. Simulated I/R reduces delta and 
kappa opiate receptor expression and their expression recovers soon after reperfusion. B. Block of 
autophagy does not affect I/R regulated opiate receptor expression and autophagic flux is 
downregulated after ischemia and recovers during reperfusion. 
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Opiate receptor expression is regulated by HDAC inhibition.  
It has been reported that the protective effect of HDACi SAHA is dependent on inducing 
autophagy. Since autophagy and OPRs correlate to each other during cellular response to I/R 
injury, we decided to test whether SAHA treatment on AC16 cells to see whether SAHA will 
affect OPRs level. Indeed, SAHA increases DOP and KOP expression around 50% and 
maintains the autophagy flux two folds during I/R by Western blots (N=3, P≤0.005) (Figure 
15A). After getting this exciting data and keeping in mind the cardioprotective effect of SAHA 
in mouse, we treated wild type mice with SAHA injection as indicated in Figure 12. SAHA 
pretreatment for 24 hours increases DOP and KOP protein around 85% and mRNA expression 
3.5 folds by Western blots and qRT-PCR(N=3, P≤0.005) (Figure 15B,C). Similarly, SAHA at 
reperfusion treatment only increases DOP and KOP expression around 65% by Western blots 
(N=3, P≤0.005) (Figure 15D). 
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Figure 15. Opiate receptor expression is regulated by HDAC inhibition. A. In cultured AC16 cells, 
SAHA increases delta and kappa opiate receptor expression and maintain the autophagic flux during 
I/R by Western blots. B. In mouse heart, SAHA pretreatment for 24 hours increases delta and kappa 
opiate receptor expression by Western blots and C. qPCR. D. In mouse heart, SAHA reperfusion only 
treatment for 24 hours increases delta and kappa opiate receptor expression by Western blots. 
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It has been shown that SAHA reduces cell death during I/R. Based on this data, we moved on 
to test whether SAHA’s cell protective effects are depended on OPRs activity. We have used 
Naloxone, an OPRs antagonist, to block their effect of OPR activation. We used LDH assay 
cell death assay as described in the methods. SAHA treatment reduces cell death after I/R by 
15% (n-3, p≤0.05). In contrast, with naloxone treatment, SAHA failed to reduce cell death 
(Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
                                     
                     
 
Figure 16. Opiate receptor expression blocked by Naloxone.LDH Cell death assay in cultured 
AC16 cells with the treatment of naloxone (OPRs-antagonist) and SAHA block opiate receptor 
expression and increase cell death.  
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 PART- II Opiate receptor expression is downregulated in diabetic mouse hearts. 
Diabetes has wide effects on the protein expression and function. We are set to test whether 
opiate receptor express levels are affected by the diabetic status. We have successfully 
generated a type II diabetic model using low dose STZ and high fat diet (Figure 17). The 
expression level of DOP and KOP protein and mRNA are downregulated around 50% in the 
diabetic mouse heart by Western blots and qRT-PCR (N=5, P≤0.005) respectively. The 
autophagy level is down-regulated around 63% in diabetic mouse heart (N=5, P≤0.005) (Figure 
17). Then we tested the possibility for SAHA to rescue the reduced protein expression of OPRs 
in diabetic mice. STZ mice were injected with 2 dose of SAHA (Figure14). At mRNA level, 
both DOP and KOP are significantly higher with the treatment of SAHA (n=3, p≤0.05) (Figure 
18-D).The expression of KOP and autophagy marker LC3II was significantly upregulated with 
SAHA compared to control group (n=3, p≤0.05). On contrast, SAHA treatment has no effect 
on the expression level of DOP and P62 (Figure 18). 
 
 
 
 
 
      
 
 
 
 
                                     
                                   Figure 17. Blood glucose level in Type II mouse model. 
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   Figure 18. Opiate receptor expression is downregulated in diabetic mouse hearts. A.    
Expression of delta and kappa opiate receptors is downregulated in the mouse heart by Western 
blots and B. qRT-PCR. The autophagy level is downregulated in diabetic mouse heart. C.SAHA 
injection induce KOP receptor and autophagy significantly in diabetic mice. D. qRT-PCR.SAHA 
upregulate OPRs mRNA level is in diabetic mouse heart. 
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Part II HDAC Inhibition and Autophagic Flux in Cardiomyocytes 
We know that the non-selective class I and II HDAC inhibitor, SAHA, induces autophagic flux 
in cardiomyocytes during I/R. However, we don’t know which class of HDAC is responsible 
for regulating autophagy. In AC16 cells, Class I and II HDAC inhibitor, SAHA and Class I 
HDAC inhibitor, apicidin, induce two-folds autophagic flux (N=3, P≤0.005). While class II 
HDAC inhibitor, MC1568 did not induce autophagic flux.  
 
Figure 19. Class I HDAC inhibitor induces autophagy flux in cardiomyocytes.A.In Ac 16 cells, 
Class I and II .HDAC inhibitors,SAHA and class I HDAC inhibitor, Apicidin induce autophagic flux. 
While class II HDAC inhibitor, MC1568 does not induce autophagic flux.B.In human ES cell- derived 
cardiomyocytes (hES-CMs), we observed similar results (N=2). 
 
Conclusions  
Delta and Kappa opiate receptors expression levels are actively regulated by ischemia 
reperfusion. HDAC inhibition increases DOP and KOP expression. In diabetic heart, DOP and 
KOP expression are reduced. Class I HDAC inhibition induces autophagic flux in 
cardiomyocytes. 
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Chapter IV 
 Discussion 
 
Patients have acute myocardial infarct and patients get on pump cardiac surgery have not only 
the risk of ischemic injury when the coronary artery is blocked or heart is arrested by 
cardioplegia solution, but also have subsequent reperfusion injury when the coronary artery is 
opened or when the heart is restarted. That is why it is very important to come up with novel 
strategies to protect the heart during this severe reperfusion injury. Novel therapies need to be 
developed to improve patient's quality of life, especially those with a contractile deficit profile 
seen before the surgery or large myocardial infarction. Targeting reperfusion injury has been 
studied for several decades and we still don’t have a standard therapy in the clinical arena [16, 
70]. Therefore, basic research and translational medicine are coming together try to find an 
effective therapies by applying experimental models that are as close to clinical reality as 
possible  [14, 144, 155].Our experimental models used in this study are designed to mimicking 
human ischemic event during myocardial infarct in tissue culture and in mouse hearts.  
Many studies have highlighted some cellular metabolic activity and proteomics profile that are 
changing during I/R [16-18] . Thus make them among the most interesting target to be 
investigated. OPRs are one of them as their protective effect have been elucidated through the 
availability of many drugs that can modulate their expression or activity especially during 
ischemic conditioning [13, 29, 39, 63, 71]. 
In our study, we have shown that I/R can modulate the expression of OPRs, specifically both 
receptor DOP and KOP were down regulated during a two hours of ischemia and tend to 
recover during the reperfusion in a time dependent fashion in our vitro system (80%). More 
interestingly, the autophagy profile was similar and goes down during Ischemia. Based on these 
data, we have hypothesized that OPR activation may cause autophagy. The autophagy during 
I/R is believed to be beneficial [127, 130, 134, 143, 147].The FDA approved anti-cancer 
HDACi, SAHA, has been shown to protect the myocardium in a large animal model by 
inducing autophagy and were able decrease the infarct size and maintain the heart physiology 
[127].That is why we thought that SAHA treatment may regulate OPRs expression and then 
subsequently autophagy. Indeed, in AC16 cell, SAHA pretreatment induces OPRs mRNA and 
protein levels, autophagic flux and reduces cell death. Moreover, in wild type mouse heart, 
pretreatment and reperfusion only treatment of SAHA upregulate the expression of opioid 
receptor at mRNA and protein level. To test the dependency of SAHA’s cardiac protective 
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effects on OPRs, we used naloxone to block the activation of OPRs. We found that SAHA 
failed to reduce cell death during I/R with the presence of naloxone. Since naloxone as a 
chemical may have some unintended effects other than blocking OPRs, it might be helpful to 
test whether knocking down DOP or KOP using siRNA blocks SAHA’s protective effects also.  
However, same as many in vitro studies, there are a lot of limitations of our AC16 cell system. 
We need to verify these results in bona fide cardiomyocytes such as neonatal rat ventricular 
myocytes (NRVM) or adult rat cardiomyocytes. 
Since diabetes has worse clinical outcome during myocardial infarction [97, 101, 102]. we 
hypothesized that opioid receptors expression is downregulated. We generated a type II DM 
mouse model using low dose STZ and high fat diet. These mice have significant increased 
fasting glucose level. We have evaluated the expression of OPRs and was dramatically down 
in this model (50%) as well as autophagy. Furthermore we have injected SAHA to check 
whether it may restore the expression of OPRs and autophagy. SAHA injection increases the 
level of mRNA and upregulate autophagy and KOP significantly but not DOP. Ideally, these 
data need to be confirmed in human diabetic myocardium. 
We also go on to check whether it is class I or class II HDACi that induce protective autophagy. 
We have used class I HDACi, apicidin and class II HDACi Mc1568. Apicidin increases 
autophagic flux up to 2 folds while Mc1568 did not. It will be interesting to see whether class 
I or class II HDACi has different effects on OPR expression. These results may lead to more 
specific autophagy inducers with less non-specific cytotoxic effects.  
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Chapter V: Significance and Future Directions 
 
We have found that Delta and Kappa opiate receptors expression levels are actively regulated 
by ischemia reperfusion. HDAC inhibition increases DOP and KOP expression. In diabetic 
heart, DOP and KOP expression are reduced. Class I HDAC inhibition induces autophagic flux 
in cardiomyocytes. These results point out that opiate receptors are attractive therapeutic targets 
for reperfusion injury and agonists of the OPRs might be used in synergy with other cardiac 
protect medications such as adenosine and HDAC inhibitors. In diabetes, HDAC inhibition 
might be useful to restore the expression of OPRs and might increase the I/R tolerance in 
diabetes. Last but not least, we may use more specific class I HDAC inhibition to treat I/R 
injury to avoid the side effects of non-selective class I and II HDAC inhibition. As mentioned 
in the discussion, we will need to verify these findings in bona fide cardiomyocytes. We will 
also need to verify the downregulation of OPRs human diabetic heart samples. Furthermore, 
the mechanisms of how HDAC inhibition regulates OPR expression needs to be elucidated. 
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